BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

USFDA grants EUA to Hong Kong's INDICAID COVID-19 Rapid Antigen Test

11 August 2021 | News

The test can be professionally used in point of care CLIA-waived settings in the U.S. for the qualitative detection of SARS-CoV-2 antigen

Hong Kong-based PHASE Scientific International has announced that its INDICAID™ COVID-19 Rapid Antigen Test (INDICAID) has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA).

Anterior nasal swab specimens may be collected by a healthcare provider or self-collected under the supervision of a healthcare professional. In regions outside of the U.S., such as Hong Kong, the test is authorized as a consumer self-test.

INDICAID requires no special instrumentation and can be performed in 20 minutes with a gentle shallow nasal swabbing vs. the deeper penetration required by other tests.

INDICAID is also one of the first rapid antigen tests to enable batch sample collection and testing at the point of care due to its unique sample collection vial which protects the sample throughout the collection and staging process. The design gives healthcare professionals the option of collecting a large number of samples concurrently and then quickly testing the individual samples in batches within a two-hour timeframe. To date, there are over two million kits sold across 30 countries worldwide.

"Our test has been globally adopted and utilized to meet a variety of emergency testing needs. From the Hong Kong government using INDICAID for healthcare worker's weekly screenings to usage across shopping malls, supermarkets and schools worldwide, our rapid test has proved to be both effective and efficient," said Dr. Ricky Chiu, founder, and chief executive officer of PHASE Scientific.